GTBPNasdaqPharmaceutical PreparationsFiscal year ends December 31

GT Biopharma, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$6.69−0.34 (-4.84%)

Close on Oct 19, 2026

Earnings

Quarterly results announced on Form 8-K, Item 2.02

Quarter	Reported	Time	Revenue	EPS (GAAP)	EPS (adjusted)
Q3 FY2025 Ended Sep 30, 2025	Nov 14, 2025	Before market open	–	–	–
Q3 FY2018 Ended Sep 30, 2018	Nov 15, 2018	Before market open	–	–	–

Announcements GT Biopharma filed with the SEC

Nov 14, 2025, 9:05 AM ET
Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Jan 27, 2025, 7:00 AM ET
Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies
Other events · EX-99.1 to Form 8-K
Jan 27, 2025, 7:00 AM ET
EX-99.2 to Form 8-K
Other events · EX-99.2 to Form 8-K
Jun 27, 2024, 9:34 AM ET
Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+
Other events · EX-99.1 to Form 8-K
Feb 1, 2024, 12:15 PM ET
Biopharma, Inc. Announces 1-for-30 Reverse Stock Split
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Dec 4, 2023, 5:00 PM ET
GTB-3650 for Treatment of CD33+ Leukemia
Other events · EX-99.1 to Form 8-K
Jan 4, 2023, 6:22 AM ET
Biopharma, Inc. Announces $6.5 Million Registered Direct Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Oct 4, 2022, 4:49 PM ET
Biopharma Announces Adjournment of Special Shareholders Meeting
Other events · EX-99.1 to Form 8-K
Nov 1, 2021, 10:17 AM ET
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K